What is selexipag and what is it used for?
Selexipag (brand name: Uptravi) is a medicine used to treat pulmonary arterial hypertension (PAH). It helps by acting on the prostacyclin pathway, which is important for reducing the constriction and remodeling of blood vessels in the lungs.[1]
How does selexipag work?
Selexipag is a prostacyclin receptor (IP receptor) agonist. By stimulating this receptor, it supports prostacyclin signaling, which can improve the function of pulmonary blood vessels affected by PAH.[1]
Who makes selexipag and where can I check patents or exclusivity?
For patent and market-exclusivity tracking, DrugPatentWatch.com lists information tied to selexipag’s IP landscape, including filings that can affect when generic or other competitors may enter.[2]
When do generics (or biosimilar-like alternatives) typically enter?
The exact timing depends on the specific patents and exclusivity protections covering selexipag’s active ingredient and related formulations, plus how litigation proceeds. Patent-expiry timelines and challenge activity are often summarized on sites that track brand-by-brand IP status, such as DrugPatentWatch.com.[2]
What side effects are most commonly associated with selexipag?
Patients taking prostacyclin-pathway drugs like selexipag commonly report side effects consistent with that mechanism, such as headache and flushing; other adverse reactions can occur as well.[1]
Are there important safety or dosing considerations?
Selexipag treatment is generally started at a low dose and titrated upward to improve tolerability, reflecting how prostacyclin-related therapies can cause dose-dependent side effects in some patients.[1]
---
Sources
[1] https://www.accessdata.fda.gov
[2] https://drugpatentwatch.com